Protocol Ledger

Biopharma Industry · Consolidated Sponsor Hub

Viatris: Clinical Trials & FDA Approval Profile

Viatris (Canonsburg, PA) sponsors 24 reconciled interventional Phase II and Phase III ClinicalTrials.gov studies (2018 to 2026), including 8 active protocols (4 recruiting now), 14 completed protocols, and 61 all-time original FDA Drugs@FDA NDA and BLA approvals.

Track in Studio / Generate Client Brief ->
Early-Stop Rate vs National (13.8%)8.3%
Median Closed Enrollment vs National (145 pts)351 participants

Verified Sponsor Execution & Regulatory Ledger

Reconciled ClinicalTrials.gov v2 & Drugs@FDA Metrics for Viatris
Sponsor MetricVerified Count / Rate
Phase II & III Protocols (2018 to 2026)24
Active Pipeline (Recruiting Now)8 (4)
Completed vs Stopped Early14 / 2 (8.3%)
Median Closed Actual Enrollment351 participants
Physical Hospital Site Disclosure98.3% named hospitals
FDA Drugs@FDA Original NDA/BLA Approvals61 (12 since 2018)

Top Partner U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Partnered With Viatris
Hospital Research SiteLocationShared Protocols
Tri-Service General HospitalTaipei3
Taipei Veterans General HospitalTaipei3

Indexed Multi-Center Phase II & III Protocols

Representative ClinicalTrials.gov v2 Studies Sponsored by Viatris
NCT IdentifierProtocol Brief TitlePhaseStatus
NCT05046795Revefenacin in Chinese Subjects With Moderate to Very Severe Chronic Obstructive Pulmonary Disease(COPD)Phase IIICOMPLETED

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Viatris across sibling Meru public-data platforms.

Explore interactive annual charts and M&A subsidiary rollups in the Viatris Interactive Dossier, benchmark peers in Immunology, Rheumatology, and Dermatology, or review the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI